View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ABGSC Media Research ... (+2)
  • ABGSC Media Research
  • Derek Laliberté
ABGSC Media Research ... (+2)
  • ABGSC Media Research
  • Derek Laliberté
ABGSC IT Research ... (+3)
  • ABGSC IT Research
  • Daniel Thorsson
  • Simon Granath
ABGSC IT Research ... (+3)
  • ABGSC IT Research
  • Daniel Thorsson
  • Simon Granath
ABGSC Media Research ... (+2)
  • ABGSC Media Research
  • Derek Laliberté
ABGSC Construct. & Real Estate Research ... (+3)
  • ABGSC Construct. & Real Estate Research
  • Fredrik Stensved
  • Oscar Lindquist

Genmab A/S: Covenant Quality Post-Sale Snapshot: $1,500m 6.250% Senior...

Genmab A/S's covenant package provides weakest protection, reflecting a CQ score of 4.34.

ABGSC Construct. & Real Estate Research ... (+3)
  • ABGSC Construct. & Real Estate Research
  • Fredrik Stensved
  • Oscar Lindquist

Genmab A/S: Covenant Quality Post-Sale Snapshot: $1,500m 6.250% Senior...

Genmab A/S's covenant package provides weakest protection, reflecting a CQ score of 4.34.

 PRESS RELEASE

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; January 29, 2026 – (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 32,806 restricted stock units and 34,307 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, ...

ABGSC IT Research ... (+3)
  • ABGSC IT Research
  • Daniel Thorsson
  • Simon Granath
ABGSC IT Research ... (+3)
  • ABGSC IT Research
  • Daniel Thorsson
  • Simon Granath
 PRESS RELEASE

Year-end report 2025, January – December

Year-end report 2025, January – December Fourth quarter Order intake decreased by 4% to SEK 854 m (893). Organically, order intake increased by 3%Net sales increased by 18% to SEK 951 m (807). Organically, net sales increased by 23%Adjusted EBIT reached SEK 268 m (163), equal to a 28.2% (20.2) adjusted operating marginEBIT reached SEK 236 m (106), equal to a 24.8% (13.2) operating marginAdjusted profit after tax totaled SEK 209 m (131). Adjustments include a non-recurring tax effect of SEK 104 m, increasing the tax expense for the period. Adjusted basic earnings per share were SEK 4.17 (2....

 PRESS RELEASE

Bokslutskommuniké 2025, januari – december

Bokslutskommuniké 2025, januari – december Kvartalet Orderingången minskade med 4 % till 854 MSEK (893). Organiskt ökade orderingången med 3 %Nettoomsättningen ökade med 18 % till 951 MSEK (807). Organiskt ökade nettoomsättningen med 23 %Justerad EBIT uppgick till 268 MSEK (163), motsvarande en justerad rörelsemarginal på 28,2 % (20,2)EBIT uppgick till 236 MSEK (106), motsvarande en rörelsemarginal på 24,8 % (13,2)Justerat resultat efter skatt uppgick till 209 MSEK (131). Justeringar inkluderar en skatteeffekt av engångskaraktär om 104 MSEK som ökar periodens skattekostnad. Justerad vinst ...

 PRESS RELEASE

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025 Company Announcement Net sales of DARZALEX® in 2025 totaled USD 14,351 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; January 21, 2026 – (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 14,351 million in 2025. Net trade sale...

ABGSC Construct. & Real Estate Research ... (+3)
  • ABGSC Construct. & Real Estate Research
  • Fredrik Stensved
  • Oscar Lindquist
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch